已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

A living WHO guideline on drugs for covid-19

指南 利托那韦 医学 2019年冠状病毒病(COVID-19) 背景(考古学) 随机对照试验 临床试验 梅德林 重症监护医学 家庭医学 内科学 病毒载量 人类免疫缺陷病毒(HIV) 病理 疾病 传染病(医学专业) 法学 政治学 古生物学 抗逆转录病毒疗法 生物
作者
Arnav Agarwal,Beverley J. Hunt,Miriam Stegemann,Bram Rochwerg,François Lamontagne,Reed Siemieniuk,Thomas Agoritsas,Lisa Askie,Lyubov Lytvyn,Yee‐Sin Leo,Helen Macdonald,Linan Zeng,Ahmed Alhadyan,A. Muna,Wagdy Amin,André Ricardo Araújo da Silva,Diptesh Aryal,Fabián Alberto Jaimes Barragán,Frédérique Jacquerioz Bausch,Erlina Burhan,Carolyn S. Calfee,Maurizio Cecconi,Binila Chacko,Duncan Chanda,Vu Quoc Dat,An De Sutter,Bin Du,Stephen B. Freedman,Heike Geduld,Patrick O. Gee,Muhammad Mohsin Haider,Matthias Götte,Nerina Harley,Madiha Hashmi,David S.C. Hui,Mohamed Ismail,Fyezah Jehan,Sushil K. Kabra,Seema Kanda,Yae‐Jean Kim,Niranjan Kissoo,Sanjeev Krishna,Krutika Kuppalli,Arthur Kwizera,Marta Lado Castro-Rial,Thiago Lisboa,Rakesh Lodha,Imelda Mahaka,Hela Manai,Marc Mendelson,Giovanni Battista Migliori,G Miño,Emmanuel Nsutebu,Jessica Peter,Jacobus Preller,N. Pshenichnaya,Nida Qadir,Shalini Sri Ranganathan,Pryanka Relan,Jamie Rylance,Saniya Sabzwari,Rohit Sarin,Manu Shankar‐Hari,Mike Sharland,Yinzhong Shen,João Paulo Souza,Ronald Swanstrom,Tshokey Tshokey,Sebastián Ugarte,Timothy M. Uyeki,Evangelina Vázquez Curiel,Sridhar Venkatapuram,Dubula Vuyiseka,Ananda Wijewickrama,Lien Tran,Dena Zeraatkar,Jessica Bartoszko,Long Ge,Romina Brignardello‐Petersen,Andrew Owen,Pierre Guy,Janet Dı́az,Letícia Kawano-Dourado,Michael Jacobs,Per Olav Vandvik
标识
DOI:10.1136/bmj.m3379
摘要

Abstract Updates This is the fourteenth version (thirteenth update) of the living guideline, replacing earlier versions (available as data supplements). New recommendations will be published as updates to this guideline. Clinical question What is the role of drugs in the treatment of patients with covid-19? Context The evidence base for therapeutics for covid-19 is evolving with numerous randomised controlled trials (RCTs) recently completed and underway. Emerging SARS-CoV-2 variants and subvariants are changing the role of therapeutics. What is new? The guideline development group (GDG) defined 1.5% as a new threshold for an important reduction in risk of hospitalisation in patients with non-severe covid-19. Combined with updated baseline risk estimates, this resulted in stratification into patients at low, moderate, and high risk for hospitalisation. New recommendations were added for moderate risk of hospitalisation for nirmatrelvir/ritonavir, and for moderate and low risk of hospitalisation for molnupiravir and remdesivir. New pharmacokinetic evidence was included for nirmatrelvir/ritonavir and molnupiravir, supporting existing recommendations for patients at high risk of hospitalisation. The recommendation for ivermectin in patients with non-severe illness was updated in light of additional trial evidence which reduced the high degree of uncertainty informing previous guidance. A new recommendation was made against the antiviral agent VV116 for patients with non-severe and with severe or critical illness outside of randomised clinical trials based on one RCT comparing the drug with nirmatrelvir/ritonavir. The structure of the guideline publication has also been changed; recommendations are now ordered by severity of covid-19. About this guideline This living guideline from the World Health Organization (WHO) incorporates new evidence to dynamically update recommendations for covid-19 therapeutics. The GDG typically evaluates a therapy when the WHO judges sufficient evidence is available to make a recommendation. While the GDG takes an individual patient perspective in making recommendations, it also considers resource implications, acceptability, feasibility, equity, and human rights. This guideline was developed according to standards and methods for trustworthy guidelines, making use of an innovative process to achieve efficiency in dynamic updating of recommendations. The methods are aligned with the WHO Handbook for Guideline Development and according to a pre-approved protocol (planning proposal) by the Guideline Review Committee (GRC). A box at the end of the article outlines key methodological aspects of the guideline process. MAGIC Evidence Ecosystem Foundation provides methodological support, including the coordination of living systematic reviews with network meta-analyses to inform the recommendations. The full version of the guideline is available online in MAGICapp and in PDF on the WHO website, with a summary version here in The BMJ . These formats should facilitate adaptation, which is strongly encouraged by WHO to contextualise recommendations in a healthcare system to maximise impact. Future recommendations Recommendations on anticoagulation are planned for the next update to this guideline. Updated data regarding systemic corticosteroids, azithromycin, favipiravir and umefenovir for non-severe illness, and convalescent plasma and statin therapy for severe or critical illness, are planned for review in upcoming guideline iterations.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
SciGPT应助wukong采纳,获得10
3秒前
4秒前
7秒前
9秒前
11秒前
12秒前
Rain完成签到,获得积分10
12秒前
李爱国应助科研通管家采纳,获得10
14秒前
小马甲应助科研通管家采纳,获得10
14秒前
深情安青应助科研通管家采纳,获得10
14秒前
天天快乐应助科研通管家采纳,获得10
14秒前
彭于晏应助科研通管家采纳,获得10
14秒前
丘比特应助科研通管家采纳,获得10
14秒前
Rondab应助科研通管家采纳,获得30
14秒前
14秒前
FashionBoy应助科研通管家采纳,获得10
14秒前
16秒前
一直向前发布了新的文献求助10
17秒前
17秒前
可爱的函函应助mellow采纳,获得10
17秒前
20秒前
20秒前
TRY发布了新的文献求助10
21秒前
毕业论文三万字完成签到,获得积分10
22秒前
JOY发布了新的文献求助10
24秒前
momo发布了新的文献求助10
24秒前
晗晗有酒窝完成签到,获得积分10
24秒前
缥缈的碧曼完成签到,获得积分10
25秒前
斯文败类应助Steven采纳,获得10
26秒前
27秒前
28秒前
天天快乐应助大喵采纳,获得10
29秒前
mellow发布了新的文献求助10
31秒前
32秒前
32秒前
非也非也6发布了新的文献求助10
32秒前
JOY完成签到,获得积分10
33秒前
猫瓜西完成签到,获得积分10
33秒前
整齐凝竹完成签到 ,获得积分10
37秒前
38秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989811
求助须知:如何正确求助?哪些是违规求助? 3531927
关于积分的说明 11255560
捐赠科研通 3270706
什么是DOI,文献DOI怎么找? 1805035
邀请新用户注册赠送积分活动 882181
科研通“疑难数据库(出版商)”最低求助积分说明 809190